| LARIMAR THERAP.I. DL-,001 |
| USA |
| Gesundheit |
| US5171251003 / A2P5PP |
| ZA71 (Frankfurt) / LRMR (NASDAQ) |
| FRA:ZA71, ETR:ZA71, ZA71:GR, NASDAQ:LRMR |
| - |
| https://larimartx.com/ |
|
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with an emphasis on Friedreich’s ataxia. The company’s core program is nomlabofusp, a protein replacement therapy des..
>Volltext.. |
| 251.92 Mio. EUR |
| 118.61 Mio. EUR |
| - |
| -161.08 Mio. EUR |
| -155.6 Mio. EUR |
| -1.79 EUR |
| 4.47 Mio. EUR |
| 83.56 Mio. EUR |
| -140.56 Mio. EUR |
| 4.57 |
| - |
| -78.42% |
| - |
| - |
| - |
| LARIMAR |
| 13.11.26 |
|